Replimune预计在2027年4月前获得永久性J编码，随着TUDRIQEV上市指标积累 (NASDAQ:REPL)
· seekingalpha.com
Replimune 2027财年第二季度财报电话会议：TUDRIQEV上市势头、早期黑色素瘤采用、现金跑道及关键风险。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...